Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

FINGOLIMOD for Relapsing-remitting multiple sclerosis: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 8,814 adverse event reports in the FDA FAERS database where FINGOLIMOD was used for Relapsing-remitting multiple sclerosis.

Most Reported Side Effects for FINGOLIMOD

Side Effect Reports % Deaths Hosp.
Fatigue 8,901 12.6% 34 921
Multiple sclerosis relapse 6,728 9.5% 52 1,787
Headache 5,993 8.5% 30 754
Dizziness 4,317 6.1% 13 627
White blood cell count decreased 3,597 5.1% 14 311
Lymphocyte count decreased 3,232 4.6% 31 499
Hypoaesthesia 3,180 4.5% 14 684
Gait disturbance 3,007 4.2% 24 754
Fall 2,715 3.8% 19 727
Memory impairment 2,623 3.7% 8 310
Malaise 2,605 3.7% 22 543
Drug ineffective 2,571 3.6% 17 282
Nausea 2,446 3.5% 18 431
Central nervous system lesion 2,416 3.4% 22 437
Pain 2,370 3.3% 17 484

Other Indications for FINGOLIMOD

Multiple sclerosis (43,123) Product used for unknown indication (16,965) Relapsing multiple sclerosis (851) Multiple sclerosis relapse (355) Secondary progressive multiple sclerosis (351) Foetal exposure during pregnancy (319) Primary progressive multiple sclerosis (66) Multiple sclerosis relapse prophylaxis (53) Progressive multiple sclerosis (20) Clinically isolated syndrome (18)

Other Drugs Used for Relapsing-remitting multiple sclerosis

OCRELIZUMAB (15,658) OFATUMUMAB (3,864) DIMETHYL (3,638) NATALIZUMAB (2,749) INTERFERON BETA-1A (2,058) GLATIRAMER (1,965) ALEMTUZUMAB (1,604) TERIFLUNOMIDE (1,320) RITUXIMAB (956) TECFIDERA (806)

Related Pages

FINGOLIMOD Full Profile All Relapsing-remitting multiple sclerosis Drugs FINGOLIMOD Demographics FINGOLIMOD Timeline